摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-氯-5-苯基-2-硫羰基-2,3-二氢-1,4-苯(异)二氮卓 | 34099-69-9

中文名称
7-氯-5-苯基-2-硫羰基-2,3-二氢-1,4-苯(异)二氮卓
中文别名
——
英文名称
1,3-dihydro-5-phenyl-2H-1,4-benzodiazepine-2-thione
英文别名
5-phenyl-1,3-dihydro-benzo[e][1,4]diazepine-2-thione;1,3-Dihydro-5-phenyl-2H-1,4-benzodiazepin-2-thion;5-Phenyl-1,2-dihydro-3H-1,4-benzodiazepin-2-thion;5-Phenyl-1.3-dihydro-2H-1.4-benzodiazepin-2-thion;5-Phenyl-1,3-dihydro-2H-1,4-benzodiazepine-2-thione;5-phenyl-1,3-dihydro-1,4-benzodiazepine-2-thione
7-氯-5-苯基-2-硫羰基-2,3-二氢-1,4-苯(异)二氮卓化学式
CAS
34099-69-9
化学式
C15H12N2S
mdl
——
分子量
252.34
InChiKey
LZANARFQFSEWHV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    236-238 °C
  • 沸点:
    379.8±52.0 °C(Predicted)
  • 密度:
    1.22±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    18
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.07
  • 拓扑面积:
    56.5
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933990090

SDS

SDS:22dd9a82e8442cdb9af81f2150db9679
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    1-(氨基烷基)-6-芳基-4-Hs-三唑并[4,3-a] [1,4]苯并二氮杂卓具有抗焦虑和抗抑郁活性。
    摘要:
    已经制备了一系列的1-(氨基烷基)-6-芳基-4H-s-三唑并[4,3-a] [1,4]苯并二氮杂并评估中枢神经系统活性。我们发现该系列的成员在旨在检测抗焦虑和抗抑郁活性的药理学测试系统中具有活性。每种类型的活性可以通过适当的取代基选择独立地变化。
    DOI:
    10.1021/jm00178a009
  • 作为产物:
    描述:
    1,3-二氢-5-苯基-1,4-苯并二氮杂卓-2-酮正丁基锂tetraphosphorus decasulfide 作用下, 以 四氢呋喃正己烷 为溶剂, 反应 16.0h, 以65%的产率得到7-氯-5-苯基-2-硫羰基-2,3-二氢-1,4-苯(异)二氮卓
    参考文献:
    名称:
    Reaction of Phosphorus Pentasulfide with Organolithiums. AnIn SituReagent for the Preparation of Thiolactams
    摘要:
    五硫化二磷在温和的条件下与四当量的正丁基锂、甲基锂或苯基锂发生反应,生成四氢呋喃溶液。新试剂可将内酰胺原位转化为硫代内酰胺,并对反应性内酰胺的类型具有显著的选择性。
    DOI:
    10.1055/s-1987-27871
点击查看最新优质反应信息

文献信息

  • PROCESS FOR PREPARATION OF TRIAZOL-BENZODIAZEPINE DERIVATIVES
    申请人:Naik Anil M.
    公开号:US20090093629A1
    公开(公告)日:2009-04-09
    An improved process for preparation of triazol-benzodiazepine derivatives, such as alprazolam, triazolam, brotizolam and etizolam, is presented. The process comprises a cyclization reaction of compound Formula B in toluene with catalytic amount of p-toluene sulphonic acid to obtain the triazol-benzodiazepine derivative of Formula C: wherein R is, and X is hydrogen or halogen.
    提供了一种改进的三唑-苯二氮䓬啡衍生物的制备过程,例如阿普唑仑、三唑安定、布罗替唑和依托唑。该过程包括在甲苯中使用催化量对甲苯磺酸进行化合物B的环化反应,以获得化合物C的三唑-苯二氮䓬啡衍生物: 其中R是, X是氢或卤素。
  • Reaction of Phosphorus Pentasulfide with Organolithiums. An<i>In Situ</i>Reagent for the Preparation of Thiolactams
    作者:O. P. Goel、U. Krolls
    DOI:10.1055/s-1987-27871
    日期:——
    Phosphorus pentasulfide reacts under mild conditions with four equivalents of n-butyllithium, methyllithium or phenyllithium giving solutions in tetrahydrofuran. The new reagents in situ convert lactams to thiolactams and show significant selectivity in the type of reactive lactams.
    五硫化二磷在温和的条件下与四当量的正丁基锂、甲基锂或苯基锂发生反应,生成四氢呋喃溶液。新试剂可将内酰胺原位转化为硫代内酰胺,并对反应性内酰胺的类型具有显著的选择性。
  • Reactions of 1,4-Benzodiazepinic<i>N</i>-Nitrosoamidines with Tosylmethyl Isocyanide: A Novel Synthesis of Midazolam
    作者:Carlos del Pozo、Javier González、Alberto Macías、Eduardo Alonso
    DOI:10.1055/s-2004-831243
    日期:——
    chlorides, with the monoanion of tosylmethyl isocyanide is described. The process gives entry to 3-(4-tosyl)imidazo[1,5-a][1,4]benzodiazepines, compounds which have not been described yet in the literature. These systems can be derivatized to the corresponding trisubstituted 1,4-benzodiazepines by alkylation or acylation of the imidazole ring. These new heterocyclic derivatives are potentially useful in
    描述了用作亚胺酰氯的合成等效物的 1,4-苯二氮杂 N-亚硝基脒与甲苯磺酰基甲基异氰化物的单阴离子的反应。该方法得到 3-(4-甲苯磺酰基)咪唑并[1,5-a][1,4]苯二氮卓类化合物,这些化合物尚未在文献中描述。这些系统可以通过咪唑环的烷基化或酰化衍生为相应的三取代的 1,4-苯并二氮杂卓。这些新的杂环衍生物在药物化学领域具有潜在的用途。此外,咪达唑仑 3 具有良好的麻醉特性,可通过化合物 7a 的脱磺酰化一步轻松制备。
  • 1-(Aminoalkyl)
    申请人:The Upjohn Company
    公开号:US04250094A1
    公开(公告)日:1981-02-10
    1-(Aminoalkyl) substituted-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines of the formula II: ##STR1## wherein R.sub.0 is selected from the group consisting of hydrogen, methyl, or ethyl; wherein R' and R" are selected from the group consisting of hydrogen and alkyl of 1 to 3 carbon atoms, inclusive; wherein R.sub.1 is selected from the group consisting of hydrogen, alkyl as defined above; wherein R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are selected from the group consisting of hydrogen, alkyl as defined above, halogen, nitro, cyano, trifluoromethyl, and alkoxy, alkylthio, alkylsulfinyl, and alkylsulfonyl, in which the carbon chain moieties are of 1 to 3 carbon atoms, inclusive, are prepared by reacting a compound of the formula: ##STR2## wherein X is chlorine or bromine and wherein R.sub.0, R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are defined as above with an amine of the formula: ##STR3## wherein R' and R" are defined as above. The new products of formula II including their pharmacologically acceptable acid addition salts and N-oxides are useful as sedatives, tranquilizers, muscle relaxants and antidepressants in mammals and birds.
    式II中的1-(氨基烷基)取代-6-苯基-4H-s-三唑并[4,3-a][1,4]苯二氮平,其中R.sub.0从氢、甲基或乙基中选择;其中R'和R"从氢和1到3个碳原子的烷基中选择;其中R.sub.1从氢和上述定义的烷基中选择;其中R.sub.2、R.sub.3、R.sub.4和R.sub.5从氢、上述定义的烷基、卤素、硝基、氰基、三氟甲基、烷氧基、烷硫基、烷基亚磺酰基中选择,其中碳链基团为1到3个碳原子,包括通过将式中R.sub.0、R.sub.1、R.sub.2、R.sub.3、R.sub.4和R.sub.5定义为上述的化合物与式为: ##STR2## 其中X为氯或溴,R.sub.0、R.sub.1、R.sub.2、R.sub.3、R.sub.4和R.sub.5如上所定义,与式为: ##STR3## 其中R'和R"如上所定义的胺反应制备而成。式II的新产品,包括其药理学上可接受的酸盐和N-氧化物,可用作哺乳动物和鸟类的镇静剂、安定剂、肌肉松弛剂和抗抑郁剂。
  • REMEDY FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND
    申请人:YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.
    公开号:EP0638560A1
    公开(公告)日:1995-02-15
    A remedy for osteoporosis containing a diazepine compound represented by general formula (I) or a pharmaceutically acceptable salt thereof as the active ingredient; a method of treating osteoporosis by administering the above compound; and the use of the compound for preparing a remedy for osteoporosis in formula (I) Ar represents aryl or heteroaryl; X represents oxygen or sulfur; W represents -N(R³⁶)-, -O- or -S-; Q represents a ring selected among (a), (b), (c) and (d), X and Y may be combined together to form =N-N=C(R⁶)-, =N-C(R⁵)=C(R⁶)-, =C(R⁵)-N=C(R⁶)-, =N-O-CO- or =N-N(R⁵)-CO-.
    一种治疗骨质疏松症的药物,含有通式(I)代表的二氮杂卓化合物或其药学上可接受的盐作为活性成分;一种通过施用上述化合物治疗骨质疏松症的方法;以及该化合物用于制备骨质疏松症药物的用途,在式(I)中 Ar 代表芳基或杂芳基;X代表氧或硫; W代表-N(R³⁶)-、-O-或-S-;Q 代表选自(a)、(b)、(c)和(d)的环,X 和 Y 可结合在一起形成 =N-N=C(R⁶)-、=N-C(R⁵)=C(R⁶)-、=C(R⁵)-N=C(R⁶)-、=N-O-CO- 或 =N-N(R⁵)-CO-。
查看更多